
Eli Lilly shows strong growth with new drugs, while Merck faces challenges ahead of KEYTRUDA patent expiry.
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with...





